CSBR Champions Oncology

Champions Oncology is a data-driven research organization that leverages an oncology research center of excellence to develop transformative technology and accelerate oncology research and development. This technology ranges from computational-based discovery platforms, unique oncology software solutions, and innovative and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms.
Company profile
Ticker
CSBR
Exchange
Website
CEO
Ronnie Morris
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics ...
Former names
CHAMPIONS BIOTECHNOLOGY, INC., CHAMPIONS SPORTS INC
SEC CIK
Corporate docs
IRS number
521401755
CSBR stock data
()
News
The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes
17 Mar 21
Stocks That Hit 52-Week Highs On Tuesday
16 Mar 21
The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study
16 Mar 21
Roth Capital Maintains Buy on Champions Oncology, Raises Price Target to $16
15 Mar 21
The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs
12 Mar 21
Press releases
Champions Oncology Reports Record Quarterly Revenue of $10.8 Million
11 Mar 21
Champions Oncology, Inc. to Host Earnings Call
11 Mar 21
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 11, 2021
5 Mar 21
Champions Oncology Announces Addition to Board of Directors
22 Feb 21
Investment data
Securities sold
Number of investors
Calendar
15 Mar 21
18 Apr 21
30 Apr 21
Financial summary
Quarter (USD) |
Jan 21 | Oct 20 | Jul 20 | Apr 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Apr 20 | Apr 19 | Apr 18 | Apr 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.43M | 7.43M | 7.43M | 7.43M | 7.43M | 7.43M |
Cash burn (monthly) | 374.67K | (positive/no burn) | (positive/no burn) | 90.67K | (positive/no burn) | (positive/no burn) |
Cash used (since last report) | 981.2K | n/a | n/a | 237.44K | n/a | n/a |
Cash remaining | 6.45M | n/a | n/a | 7.19M | n/a | n/a |
Runway (months of cash) | 17.2 | n/a | n/a | 79.3 | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Mar 21 | Philip P. Breitfeld | Common Stock | Payment of exercise | Dispose F | No | No | 11.35 | 1,340 | 15.21K | 2,827 |
23 Mar 21 | Philip P. Breitfeld | Common Stock | Option exercise | Aquire M | No | No | 3.65 | 4,167 | 15.21K | 4,167 |
23 Mar 21 | Philip P. Breitfeld | Option to purchase Common Stock Common Stock | Option exercise | Dispose M | No | No | 3.65 | 4,167 | 15.21K | 0 |
19 Jan 21 | Abba David Poliakoff | Common Stock | Payment of exercise | Aquire F | No | No | 11.53 | 8,873 | 102.31K | 81,274 |
19 Jan 21 | Abba David Poliakoff | Common Stock | Option exercise | Aquire M | No | No | 5.43 | 10,000 | 54.3K | 90,147 |
19 Jan 21 | Abba David Poliakoff | Common Stock | Option exercise | Aquire M | No | No | 3.21 | 10,000 | 32.1K | 80,147 |
19 Jan 21 | Abba David Poliakoff | Common Stock | Option exercise | Aquire M | No | No | 1.59 | 10,000 | 15.9K | 70,147 |
19 Jan 21 | Abba David Poliakoff | Option to purchase Common Stock Common Stock | Option exercise | Dispose M | No | No | 5.43 | 10,000 | 54.3K | 0 |
19 Jan 21 | Abba David Poliakoff | Option to purchase Common Stock Common Stock | Option exercise | Dispose M | No | No | 3.21 | 10,000 | 32.1K | 0 |
19 Jan 21 | Abba David Poliakoff | Option to purchase Common Stock Common Stock | Option exercise | Dispose M | No | No | 1.59 | 10,000 | 15.9K | 0 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
53.3% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 47 |
Opened positions | 6 |
Closed positions | 5 |
Increased positions | 12 |
Reduced positions | 19 |
13F shares |
Current |
---|---|
Total value | 87.35M |
Total shares | 7.13M |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners |
Shares | Value |
---|---|---|
Battery Management | 2.42M | $26.13M |
NEA Management | 1.71M | $18.49M |
BLK Blackrock | 465.46K | $5.02M |
Vanguard | 432.17K | $4.66M |
Tocqueville Asset Management | 252.46K | $2.72M |
Renaissance Technologies | 221.75K | $2.39M |
Roubaix Capital | 206.5K | $2.23M |
Millrace Asset | 182.34K | $1.97M |
Dimensional Fund Advisors | 131.51K | $1.42M |
NTRS Northern Trust | 107.26K | $1.16M |
Financial report summary
?Competition
Vyant BioRisks
- We historically incurred losses from operating activities, may require significant capital and may never achieve sustained profitability.
- We may incur greater costs than anticipated, which could result in sustained losses.
- We may not be able to implement our business strategies which could impair our ability to continue operations.
- Our business could be adversely impacted by changes in FDA’s regulatory oversight of laboratory-developed tests such as our POS services that are currently under consideration or by other changes in the regulatory requirements applicable to our POS services imposed by the FDA or regulatory authorities in other countries in which our services are provided.
- Our laboratories are subject to regulation and licensure requirements, and the healthcare industry is highly regulated; we may face substantial penalties, and our business activities may be impacted, if we fail to comply.
- If our laboratory facilities are damaged or destroyed, or we have a dispute with one of our landlords, our business would be negatively affected.
- Any health crisis impacting our colony of laboratory mice could have a negative impact on our business.
- We have limited experience marketing and selling our products and may need to rely on third parties to successfully market and sell our products and generate revenues.
- We will continue to be dependent upon key employees.
- Because our industry is very competitive and many of our competitors have substantially greater capital resources and more experience in research and development, we may not succeed in selling or increasing sales of our products and technologies.
- If we are unable to protect our intellectual property, we may not be able to compete as effectively.
- If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
- Claims by others that our products infringe their patents or other intellectual property rights could adversely affect our financial condition.
- Patients are unable to obtain reimbursement from third-party payers for our services, limiting the market acceptance of our services, and as a result we may not achieve significant revenues.
- TOS studies are subject to cancellation based on changes in customer’s development plans.
- Our ability to use our net operating loss carry-forwards and certain other tax attributes may be limited.
- We have a limited market for our common stock, which makes our securities very speculative.
- Investment in our common stock may be diluted if we issue additional shares in the future.
- Our stock price is volatile and therefore investors may not be able to sell their common stock at or above the price they paid for it.
- Certain provisions of our charter and bylaws and of our contractual agreements contain provisions that could delay and discourage takeover attempts and any attempts to replace our current management by shareholders.
- Our management and three significant stockholders collectively own a substantial majority of our common stock.
- We have not paid any cash dividends in the past and have no plans to issue cash dividends in the future, which could cause the value of our common stock to have a lower value than other similar companies which do pay cash dividends.
- If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they change their recommendations regarding our common stock adversely, the price of our common stock and trading volume could decline.
Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
analytic, biomarker, database, direction, dynamic, eased, economy, effort, evolve, experimental, foreseeable, genetic, guide, innovative, interrogate, lifted, LLC, Lumin, mandatory, molecular, negative, negatively, partially, pharmacology, phenotypic, preclinical, quarantine, resistance, reveal, shelter, therapeutic, transforming, unpredictable, vast, vivo
Removed:
accrual, forward, improve, moving, nil, POS
Financial reports
10-Q
2021 Q3
Quarterly report
15 Mar 21
10-Q
2021 Q2
Quarterly report
14 Dec 20
10-Q
2021 Q1
Quarterly report
14 Sep 20
10-K
2020 FY
Annual report
28 Jul 20
10-Q
2020 Q3
Quarterly report
16 Mar 20
10-Q
2020 Q2
Quarterly report
16 Dec 19
10-Q
2020 Q1
Quarterly report
16 Sep 19
10-K
2019 FY
Annual report
29 Jul 19
10-Q
2019 Q3
Quarterly report
18 Mar 19
10-Q
2019 Q2
Quarterly report
17 Dec 18
Current reports
8-K
Champions Oncology Reports Record Quarterly Revenue of $10.8 Million
11 Mar 21
8-K
Departure of Directors or Certain Officers
12 Feb 21
8-K
Champions Oncology Reports Record Quarterly Revenue of $10.1 Million
14 Dec 20
8-K
Submission of Matters to a Vote of Security Holders
21 Oct 20
8-K
Financial Statements and Exhibits
15 Oct 20
8-K
Champions Oncology Reports Record Quarterly Revenue of $9.5 Million
14 Sep 20
8-K
Champions Oncology Reports Quarterly Revenue of $8.8 Million
27 Jul 20
8-K
Unregistered Sales of Equity Securities
30 Mar 20
8-K
Champions Oncology Reports Record Quarterly Revenue of $9.0 Million
12 Mar 20
8-K
Regulation FD Disclosure
3 Jan 20
Registration and prospectus
424B4
Prospectus supplement with pricing info
9 Jun 16
S-1/A
IPO registration (amended)
23 May 16
S-1
IPO registration
25 Apr 16
424B3
Prospectus supplement
14 Oct 15
POS AM
Prospectus update (post-effective amendment)
24 Sep 15
8-A12B
Registration of securities on exchange
19 Aug 15
424B3
Prospectus supplement
18 May 15
S-1
IPO registration
10 May 15
D
$14M in equity / options, sold $14M, 11 investors
24 Mar 15
D
$2M in debt / options / securities to be acquired, sold $2M, 2 investors
11 Dec 14
Proxies
DEFM14A
Proxy related to merger
10 Sep 20
DEFA14A
Additional proxy soliciting materials
10 Sep 20
DEF 14A
Definitive proxy
28 Aug 20
DEF 14A
Definitive proxy
28 Aug 19
DEF 14A
Definitive proxy
27 Aug 18
DEFR14A
Revised proxy
30 Aug 17
DEF 14A
Definitive proxy
27 Aug 17
DEF 14A
Definitive proxy
24 Aug 16
DEFR14A
Revised proxy
31 Aug 15
DEFA14A
Additional proxy soliciting materials
30 Aug 15
Other
EFFECT
Notice of effectiveness
8 Jun 16
CORRESP
Correspondence with SEC
7 Jun 16
CORRESP
Correspondence with SEC
7 Jun 16
CORRESP
Correspondence with SEC
22 May 16
UPLOAD
Letter from SEC
4 May 16
EFFECT
Notice of effectiveness
12 Oct 15
EFFECT
Notice of effectiveness
18 May 15
CORRESP
Correspondence with SEC
24 Mar 15
UPLOAD
Letter from SEC
24 Mar 15
UPLOAD
Letter from SEC
23 Mar 15
Ownership
4
CHAMPIONS ONCOLOGY / Philip P. Breitfeld ownership change
25 Mar 21
4
CHAMPIONS ONCOLOGY / Abba David Poliakoff ownership change
8 Feb 21
4
CHAMPIONS ONCOLOGY / Philip P. Breitfeld ownership change
17 Dec 20
4
CHAMPIONS ONCOLOGY / Daniel Newman Mendelson ownership change
10 Dec 20
4
CHAMPIONS ONCOLOGY / DAVID SIDRANSKY ownership change
10 Dec 20
4
CHAMPIONS ONCOLOGY / JOEL ACKERMAN ownership change
10 Dec 20
4
CHAMPIONS ONCOLOGY / Abba David Poliakoff ownership change
10 Dec 20
4
CHAMPIONS ONCOLOGY / Philip P. Breitfeld ownership change
10 Dec 20
4
CHAMPIONS ONCOLOGY / SCOTT R TOBIN ownership change
10 Dec 20
4
CHAMPIONS ONCOLOGY / JOEL ACKERMAN ownership change
3 Nov 20
Transcripts
2021 Q1
Earnings call transcript
14 Sep 20
2020 Q4
Earnings call transcript
27 Jul 20
2020 Q2
Earnings call transcript
16 Dec 19
2020 Q1
Earnings call transcript
16 Sep 19
2019 Q4
Earnings call transcript
15 Jul 19
2019 Q3
Earnings call transcript
18 Mar 19
2019 Q2
Earnings call transcript
17 Dec 18
2019 Q1
Earnings call transcript
13 Sep 18
2018 Q4
Earnings call transcript
27 Jul 18
2018 Q3
Earnings call transcript
15 Mar 18
Reddit threads
Daily Discussion Thread - March 11th, 2021
11 Mar 21
Daily Discussion Thread - March 10th, 2021
10 Mar 21
Daily Discussion Thread - March 9th, 2021
9 Mar 21
Daily Discussion Thread - March 8th, 2021
8 Mar 21
Daily Discussion Thread - December 14th, 2020
14 Dec 20
Daily Discussion Thread - December 11th, 2020
11 Dec 20